Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment

Sergey Ivanovskiy; Ilya Yaichkov; Anton Shetnev; Mikhail Korsakov

doi:10.52957/2782-1900-2024-4-4-60-67

UDC 547.867.4

DEVELOPMENT OF THE CHROMATOGRAPHIC SEPARATION METHODOLOGY AND IMPURITY PROFILING OF 5-(5-TRIFLUOROMETHYL-ISOXAZOL-3-YL)FURAN-2-SULFONAMIDE, A DRUG CANDIDATE FOR THE GLAUCOMA TREATMENT Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment

АА Аа

Published in From Chemistry Towards Technology Step-By-Step · Volume 4, Issue 4 · Pages 60–67 · Rubric: Scientific articles

DOI: https://doi.org/10.52957/2782-1900-2024-4-4-60-67

Received: 01.11.2023 Accepted: 15.11.2023 Published: 23.12.2023 Language of publication: RUS

Authors

Sergey Ivanovskiy

Ilya Yaichkov

Anton Shetnev

Mikhail Korsakov

Sergey Ivanovskiy

Academic degree: candidate of chemical sciences

Yaroslavl State Pedagogical University named after K.D. Ushinsky Associate Professor · Yaroslavl

Ilya Yaichkov

Academic degree: candidate of pharmaceutical sciences

Yaroslavl State Pedagogical University named after K.D. Ushinsky Researcher · Yaroslavl

Anton Shetnev

Academic degree: candidate of chemical sciences

Yaroslavl State Pedagogical University named after K.D. Ushinsky Associate Professor · Yaroslavl

Yaroslavskiy gosudarstvennyy medicinskiy universitet Minzdrava Rossii Russian Federation

Mikhail Korsakov

Academic degree: doctor of chemical sciences

Yaroslavl State Pedagogical University named after K.D. Ushinsky Professor · Yaroslavl

ABSTRACT

Glaucoma is the leading cause of irreversible blindness. Early diagnosis and effective treatment can reduce the progression of the disease and prevent irreversible decay of visual functions. Indeed, human carboanhydrase isoform II is a classical target for glaucoma treatment. We proposed a compound molecule 5 (5 trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide under the project name B016, which showed high activity as a human carboanhydrase II inhibitor by in vitro tests. Our team is currently conducting development and preclinical studies of a medicinal product in the eye drops form based on this compound. One of the stages of pharmaceutical research is the development of quality control methods for both the pharmaceutical substance and the finished dosage form. We have developed a chromatographic separation procedure, which can be used for quality control of active pharmaceutical substance by quantification indicators. We also determined the impurity profile, i.e. the structure of the impurities found in the reaction product of compound B016.

KEYWORDS

carboanhydrase, glaucoma, quality control, impurity profile, high-performance liquid chromatography

Text

Text (PDF)

Read Download

1. Schellack, N., Schellack, G. & Bezuidenhout, S. (2015) Glaucoma: A brief review, SA Pharmaceutical Journal, (82), pp. 18-22. DOI: 10520/EJC174862.

2. Kurysheva, N.I. (2020) Carboanhydrase inhibitors in glaucoma treatment. Review. Part 1, Oftal`mologiya, 17(3), pp. 542-549. DOI:https://doi.org/10.18008/1816-5095-2020-3S-542-549 (in Russian).

3. Kurysheva, N.I. (2020) Carboanhydrase inhibitors in glaucoma treatment. Review. Part 2, Oftal`mologiya, 17(4), pp. 676-682. DOI:https://doi.org/10.18008/1816-5095-2020-4-676-682 (in Russian).

4. Scozzafava, A. & Mastrolorenzo, C.T. (2006) Supuran. Carbonic anhydrase inhibitors and activators and their use in therapy, Expert Opin. Ther., (16), pp. 1627-1664. DOI:https://doi.org/10.1517/13543776.16.12.1627.

5. Krylov, E.N. & Virzum L.V. (2021) Quantum chemical analysis of the interaction of alkylarylsulfonamides with α-carboanhydrase HCA II, Butlerovskie soobshheniya, 66(5), pp. 11-23. DOI:https://doi.org/10.37952/ROI-jbc-01/21-66-5-11 (in Russian).

6. Komshina, L.A., Martazova, V.V., Proskurina, I.K., Korsakov, M.K. & Kotov, A.D. (2020) Synthesis of 3 arylisoxazoles and their sulfamide derivatives, Butlerovskie soobshheniya, 63(9), pp.10-18. DOI:https://doi.org/10.37952/ROI-jbc-01/20-63-9-10 (in Russian).

7. Komshina, L.A., Vasilieva, E.A., Proskurina, I.K., Kotov, A.D. & Korsakov, M.K. (2021) Regioselectivity of sulfonyl chlorination of 3-aryl-5-N-acylaminoisoxazoles, Butlerovskie soobshheniya, 67(8), pp. 123-128. DOI:https://doi.org/10.37952/ROI: jbc-01/21-67-8-123 (in Russian).

8. Komshina, L.A., Vasilieva, E.A., Proskurina, I.K., Blumina, M.V., Kotov, A.D. & Korsakov, M.K. 2022. Regioselectivity of 1-Aryl-6-pyrazol-1-yl-pyridazines sulfonyl chlorination, Butlerovskie soobshheniya, 69(2), pp. 15-21. DOI:https://doi.org/10.37952/ROI: jbc-01/22-69-2-15 (in Russian).

9. Krasavin, M., Korsakov, M., Dorogov, M., Tuccinardi, T., Dedeoglu, N. & Supuran, C.T. (2015) Probing the «bipolar» nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms, Eur. J. Med. Chem., (101), pp. 334-347. DOI:https://doi.org/10.1016/j.ejmech.2015.06.022.

10. Krasavin, M., Korsakov, M., Zvonaryova, Z., Semyonychev, E., Tuccinardi, T., Kalinin, S. & Supuran, C.T. (2017) Human carbonic anhydrase inhibitory profile of mono- and bis-sulfonamides synthesized via a direct sulfochlorination of 3- and 4-(hetero)arylisoxazol-5-amine scaffolds, Bioorg. Med. Chem., 25(6), pp. 1914-1925. DOI:https://doi.org/10.1016/j.bmc.2017.02.018.

11. Dorogov, M.V. & Krasavin, M.Y. (2017) Aromatic derivatives of sulfonamides inhibitors of carboanhydrase II (CA II), their preparation and application methods. 2607630 RU (in Russian).

PDF Text JATS XML

Editor in chief

Dmitry Berezin

Deputy Editor in Chief

Igor Abramov

abramovig@ystu.ru

Executive secretary

Zhanna Chirkova

chirkovazhv@ystu.ru

4467

downloads

GOST

Ivanovskiy S. A., Yaichkov I. I., Shetnev A. A., Korsakov M. K. Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment // From Chemistry Towards Technology Step-By-Step. 2024. no. 4. pp. 60-67. DOI: https://doi.org/10.52957/2782-1900-2024-4-4-60-67. (Date of access 23.09.2026).

MLA

Sergey Ivanovskiy, Yaichkov I. I., Shetnev A. A., Korsakov M. K.. "Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment." From Chemistry Towards Technology Step-By-Step 4.4 (2024): 60-67. DOI: https://doi.org/10.52957/2782-1900-2024-4-4-60-67.

APA

Ivanovskiy S. A., Yaichkov I. I., Shetnev A. A., Korsakov M. K. (2024). Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment. From Chemistry Towards Technology Step-By-Step, 4(4), 60-67. https://doi.org/10.52957/2782-1900-2024-4-4-60-67

Chicago

Sergey Ivanovskiy, Yaichkov I. I., Shetnev A. A., Korsakov M. K.. "Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment." From Chemistry Towards Technology Step-By-Step 4, no. 4 (2024): 60-67. https://doi.org/10.52957/2782-1900-2024-4-4-60-67.

WIKI

{{cite journal | author = Ivanovskiy S. A., Yaichkov I. I., Shetnev A. A., Korsakov M. K. | title = Development of the chromatographic separation methodology and impurity profiling of 5-(5-trifluoromethyl-isoxazol-3-yl)furan-2-sulfonamide, a drug candidate for the glaucoma treatment | journal = From Chemistry Towards Technology Step-By-Step | year = 2024 | volume = 4 | issue = 4 | pages = 60-67 | doi = 10.52957/2782-1900-2024-4-4-60-67 }}

Copy

Export: BibTeX EndNote RefMan RusMARC

Confirmation